FEATURE ARTICLES
Don't wait until manufacturing execution system (MES) configuration to answer these 7 questions. Define your manufacturing process before digitizing it.
- DEA Reveals Hidden Costs Of Analytical Validation Guidelines
- Qualification And Validation Of Depyrogenation Tunnels And Autoclaves
- Why CMC Tech Transfer Should Begin With The End In Mind
- Engineering Better ADCs, Part 2: Characterization, CMC, And More
- FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
- August 2026 — CDMO Opportunities And Threats Report
- ICH M4Q(R2) And M16 Modernize The CTD For Digital Submissions
PHARMA ONLINE WHITE PAPERS
-
Normalized Data In Microbial Continuous Monitoring
Learn how EU GMP Annex 1 (2022) redefines cleanroom air monitoring standards and emphasizes continuous viable sampling in Grade A and B environments to ensure aseptic integrity and compliance.
-
An Integrated Analytical Approach To Lipase Risk Management In Biologics Development9/8/2026
Conventional HCP testing cannot confirm whether residual lipases remain enzymatically active. Here, the authors examine why functional activity data are essential for managing polysorbate-related stability risk in biologics development.
-
Deciphering Nanoparticle Properties With AF45/6/2026
Discover how risk‑based, phase‑appropriate synthesis enables safe, efficient production of highly potent compounds while balancing speed, worker safety, and regulatory readiness in early development.
-
Antibiotic Potency Testing By Microbial Assay9/24/2026
Selecting a potency assay for antibiotic drug substances and products carries regulatory, operational, and lifecycle implications that extend well beyond the laboratory.
-
SMB Technology: Optimizing API Purification6/13/2025
Explore how Simulated Moving Bed (SMB) technology can enhance API production while overcoming common misconceptions about chromatographic purification.
-
Navigating The Development Of Dry Powder For Inhalation9/9/2026
A CDMO-authored framework for navigating dry powder inhaler development, covering target product profile definition, API characterization, particle engineering technology selection, and encapsulation considerations.
PHARMA ONLINE APP NOTES & CASE STUDIES
- Characterization And Impurity Profiling Of Combined Amylin And GLP-1 Analogs
- Microbial Recovery And Flow Performance With Membranes
- Developing CAR T Therapies With A Cell Therapy Manufacturing Platform
- Fast And Scalable Fc Quantitation In Supernatants
- Enhancing Novel Developability Through Automated MS Analytics
NEWSLETTER ARCHIVE
- 10.12.26 -- Smarter Facility Design Starts With Better Process Control
- 10.10.26 -- Pharmaceutical Online Newsletter - Best Of September
- 10.09.26 -- Accelerate Pharma Innovation With Digital Solutions
- 10.09.26 -- ICH M4Q(R2) And M16 Modernize The CTD For Digital Submissions
- 10.08.26 -- What Does Digital CMC Maturity Look Like?
INDUSTRY NEWS
-
Let Your Voice Help Shape Pharma Manufacturing
Pharmaceutical Online hosts live virtual panels with industry experts on important topics and challenges, and we want to know what topics are important to you. Please consider taking a few minutes of your time to tell us what they are.
-
ISPE Announces 2026 FOYA Winners
These awards recognize pharmaceutical and biopharmaceutical manufacturing projects that demonstrate excellence across innovation, operations, supply chain, Pharma 4.0, and social impact.
-
Høeg In, Pazdur Out At The FDA
What an eventful week it has been at the FDA, with Richard Pazdur, M.D., resigning after weeks in his position as director of Center for Drug Research and Evaluation (CDER), and his vacancy being quickly filled by acting director Tracy Beth Høeg, M.D.
-
9 Drugs Granted Fast Track By FDA's Voucher Program
With targets like pancreatic cancer, deafness, blindness, infertility and vaping addiction, these drugs were chosen due to an unmet need, addressing a public health crisis, boosting domestic manufacturing or increasing affordability.
-
Leaders In The Excipient Market: Region And Type
Though North America led the market with a 38.32% market share of $3.15 billion in 2024, Asia Pacific is expected to have the fastest growth in the upcoming years.
PHARMACEUTICAL ONLINE CONTENT COLLECTIONS
Explore how sterility assurance, including sterilization validation and environmental monitoring, is essential for controlling microbial contamination in mammalian cell production to ensure patient safety. Check out the latest e-book from Pharmaceutical Online.
More Content CollectionsSUPPLIER NEWS
-
Contec Launches Sterile ReadySAT™ With PeridoxRTU® Sporicidal Wipes For Cleanrooms10/7/2026
Contec, Inc. announces the launch of sterile ReadySAT™ with PeridoxRTU® Sporicidal Wipes. Validated sterile and suitable for ISO 3-8 cleanrooms, the wipes support surface disinfection in the most critical cleanroom environments.
-
Upperton Unveils New Brand Identity Reflecting Evolution Into Specialist CDMO10/6/2026
Upperton has unveiled a new brand identity at CPHI Milan, marking a significant milestone in the company's evolution into a specialist, end-to-end contract development and manufacturing organisation (CDMO) focused on solving the challenges of molecule development across oral, nasal, pulmonary and parenteral dosage forms.
-
Hovione To Commission World's First ConsiGma® CDC Flex, Bringing Next-Generation Continuous Tableting To The U.S.10/5/2026
Hovione, a globally integrated pharmaceutical contract development and manufacturing organization (CDMO), today announced it will commission the world’s first ConsiGma® CDC Flex – a next generation continuous tableting line – at its East Windsor, New Jersey campus in late 2027. The line will be installed at 89 Twin Rivers, Hovione's recently opened facility, expanding the company´s drug product capabilities and strengthening its integrated pharmaceutical development and manufacturing hub in the U.S.
-
Agilent Expands Oligonucleotide Manufacturing Capabilities With New Boulder Lab10/5/2026
Agilent Technologies Inc. (NYSE: A) today announced the addition of new laboratory space in Boulder, Colorado, to support the expansion of its oligonucleotide manufacturing capabilities. The facility is expected to support the development and scale-up of emerging manufacturing technologies for oligonucleotide therapeutics, initially focusing on enzymatic ligation.